Previous 10 | Next 10 |
Live Conference Call and Webcast at 5:00 p.m. EDT Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoi...
Overall Response Rate (ORR) of 60% Observed in Patients with Relapsed or Refractory (R/R) EBV+ PTLD Consistent with Previously Reported Studies Completion of All Pre-Approval Inspections Required to Support EU Marketing Authorization Application; Anticipated European Commissio...
Bluebird Bio (BLUE), Clovis Oncology (NASDAQ:CLVS) and Chimerix (CMRX) are trading lower in the morning hours Thursday after Truist said that the three biotechs are at the risk of running out of cash within the next six months. The analysis of 118 companies developing cancer medications exclu...
Atara Biotherapeutics (NASDAQ:ATRA), a biotech focused on immunotherapies, continues to trade lower on Monday after announcing that German conglomerate Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) decided to end a licensing deal with the company for two of its CAR T-cell therapies. In reaction, H.C...
Atara Biotherapeutics (NASDAQ:ATRA) on Thursday said its collaboration partner Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) had decided to end the exclusive worldwide licensing agreement between the companies to develop CAR T-cell therapies. ATRA stock slides 15.4% to $4.34 in aftermarket trad...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it received notification of Bayer’s intenti...
Seth Klarman’s 13F portfolio value decreased from $10.13B to $9.30B this quarter. Baupost Group increased Fiserv, Dropbox, Encompass Health, Nuvation Bio, and ironSource while reducing Joby Aviation and dropping Pershing Square Tontine and NortonLifeLock. The portfolio cont...
Citi has downgraded Atara Biotherapeutics to neutral from buy due to questions over the BLA filing of its T-cell immunotherapy tab-cel (tabelecleucel). The firm also cut its target price to $8 from $23 (~16% upside based on Friday's close). Analyst Yigal Nochomovitz wrote that the U.S. FDA ha...
The following slide deck was published by Atara Biotherapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Atara Biotherapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Atara Biotherapeutics, Inc. (ATRA) Q1 2022 Results Conference Call May 5, 2022 4:30 PM ET Company Participants Eric Hyllengren - VP of IR and Finance Pascal Touchon - President and CEO Utpal Koppikar - Chief Financial Officer Jakob Dupont - EVP and Global Head of Research and Development AJ J...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...